Method for predicting curative effect of stage II colorectal cancer based on ZNF326 protein

Abstract

The invention discloses a method for using ZNF326 protein as a stage-II colorectal cancer curative effect prediction marker, application of protein to preparation of a colorectal cancer curative effect monitoring reagent is detected based on the prediction marker, and a full-scanning data independent acquisition (DIA) quantitative proteomics technology of a high-resolution mass spectrum is adopted. The change of serum sample molecular characteristics before and after chemotherapy of a plurality of II-stage colorectal cancer patients is studied, and the significant change (plt; 0.05), then several different proteins are randomly selected and verified through a PRM proteomics method, the result shows that the change trends of the SerpinB1, PCNA and PPIaseB are consistent, ROC curve analysis is utilized to find that the ZNF326 protein can well predict the curative effect of a patient suffering from the colon cancer, and the ZNF326 protein can be used for treating the colon cancer. And a specific, rapid and noninvasive detection means is provided for predicting the treatment effect and prognosis of the stage II colorectal cancer.

Description

technical field [0001] The present invention relates to the technical field of methods for predicting curative effect of stage II colorectal cancer, in particular to a method based on ZNF326 protein as a predictive marker for curative effect of stage II colorectal cancer. Background technique [0002] In China, colorectal pain is the third largest tumor, and its morbidity and mortality have been increasing year by year in recent years. Recently, there are still many problems to be solved in the clinical work of colorectal cancer. Non-invasive biomarkers for diagnosis, fecal occult blood test and colonoscopy are relatively recognized methods for early diagnosis at present. Multiple large-sample clinical research data show that screening among people over 50 years old can reduce the incidence of colorectal cancer rate and mortality, fecal occult blood examination is widely used because of its convenient operation and low cost, but its low sensitivity and specificity make its c...

AI Technical Summary

Problems solved by technology

[0002] In China, colorectal pain is the third largest tumor, and its morbidity and mortality have been increasing year by year in recent years. Recently, there are still many problems to be solved in the clinical work of colorectal cancer. Non-invasive biomarkers for diagnosis, fecal occult blood test and colonoscopy are relatively recognized methods for early diagnosis at present. Multiple large-sample clinical research data show that screening among people over 50 years old can reduce the incidence of colorectal cancer rate and mortality, fecal occult blood examination is widely used because of its convenient operation and low cost, but its low sensitivity and specificity make its clinical value limited. Colonoscopy is the gold standard for early diagnosis of colorectal cancer, but it is difficult to operate and The high cost and the risk of complications lead to poor patient compliance, and it is difficult to become a routine method for population screening. Second, there is still a lack of effective prognosis and chemotherapy efficacy evaluation indicators. Currently, clinical evidence is mainly based on clinical disease indicators (such as tumor size, Lymph node metastasis for several days, distant metastasis, tissue grade, etc.) TNM staging is used to judge the prognosis of the disease and guide clinical treatment, but according to this staging, there is great heterogeneity in the prognosis of patients, and it cannot predict the response of tumor patients to chemotherapy The complementary treatment model of traditional Chinese medicine and western medicine has been widely used clinically. Even so, a considerable number of patients, especially advanced colorectal cancer, develop drug resistance during treatment and eventually die due to disease progression. Therefore, it is necessary to look for effective markers Therefore, we propose a method based on ZNF326 protein as a predictive marker for the efficacy of stage II colorectal cancer